An individualized and customized approach should be used when selecting antibiotics for treatment of Acinetobacter infections
The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
Till the early 1970s, nosocomial Acinetobacter infections
were successfully treated with antibiotics like gentamicin, minocycline, nalidixic acid and ampicillin3.
According to studies, acinetobacter infections
are not uncommon in preterm ICUs and there are reports of infant deaths in other countries.
Resistance to carbapenem class of antibiotics makes multidrug resistant acinetobacter infections
difficult to treat.
baumannii keeps on changing, local surveillance studies conducted at regular intervals will help in deciding the most adequate therapy for Acinetobacter infections
Worldwide, treatment of multidrug resistant Acinetobacter infections
poses a great therapeutic challenge to clinicians.
Until further data become available, no firm recommendations can be made with regard to the testing or clinical utility of tigecycline, either alone or in combination with polymyxin, the carbapenems (regardless of the mode of delivery), rifampicin (or possibly fosfomycin) for life-threatening MDR Acinetobacter infections
The major challenge in treating Acinetobacter infections
is that most strains are MDR.
Clinical and molecular epidemiology of acinetobacter infections
sensitive only to polymyxin B and sulbactam.
Coverage includes avian influenza, severe acute respiratory syndrome (SARS), changing patterns of respiratory viral infections in transplant recipients, West Nile virus, emergence of novel retroviruses, community- associated methicillin-resistant Staphylococcus aureus, the emerging role of Klebsiella in liver abscess, zygomycosis, emerging food- and waterborne protozoan diseases, multidrug-resistant Acinetobacter infections
in US military personnel, and adverse events in smallpox vaccination.
SAN FRANCISCO -- Antibiotic resistance increased rapidly in nosocomial Acinetobacter infections
from 1994 to 2004, growing almost fourfold, according to a report from the Centers for Disease Control and Prevention.